Furthermore, Rosemarie Krupar’s studies highlighted the clinical significance of glycolysis-driven immunosuppression in HNSCC through genomic profiling, showing improved survival in patients with favorable immune and metabolic genetic profiles (high CD8A, high mitochondrial-rich COX5B, low GLUT1) (24). This evidence concerns the gene SLC2A1 and head and neck squamous cell carcinoma.